Barbadin

SKU: orb2901621

Description

Barbadin is a novel and selective β-arrestin/β2-adaptin interaction inhibitor, has IC50 values of 19.1 μM for β-arrestin1 and 15.6 μM for β-arrestin2. Barbadin blocks agonist-promoted endocytosis of the prototypical β2-adrenergic, V2-vasopressin and angiotensin-II type-1 receptors. Barbadin can induce apoptosis.

Key Properties

• CAS Number: 356568-70-2
• MW: 333.41
• Purity: >98% (HPLC)
• Formula: C₁₉H₁₅N₃OS
• SMILES: Nn1cnc2scc(-c3ccc(Cc4ccccc4)cc3)c2c1=O
• Solubility: In Vitro: DMSO : 50 mg/mL (149.97 mM; Ultrasonic )

Bioactivity

• In Vitro:
  Barbadin (4 h) treatment reduces cell viability and induces apoptosis. Barbadin (2 h) treatment arrests breast cancer cells in G0/G1 phase. Apoptosis Analysis. Cell line: MDA MB-231 cells. Concentration: Incubation time: 4 hours. Result: Exhibited morphological characteristics of apoptosis including shrinkage, rounding and detachment, the percent of cell viability was reduced to 69.1% and apoptosis was developed in 29.9% of cells starved with EBSS (Earle's balanced salt solution). Cell Cycle Analysis Cell line: MDA MB-231 cells. Concentration: Incubation time: 2 hours. Result: Arrested 63.7% of cells in G0/G1 phase.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only